RLFTY (Relief Therapeutics Holding) Moat Score : 2/10 (As of Jun. 27, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Relief Therapeutics Holding Moat Score?

Relief Therapeutics Holding has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Relief Therapeutics Holding has No Moat: Relief Therapeutics lacks significant market leadership or proprietary technology. The company does not exhibit strong brand strength or customer loyalty, and there are no significant regulatory barriers or exclusive licenses. Its competitive advantages are weak and transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Relief Therapeutics Holding might have No Moat - Very weak/transient advantages.

Competitive Comparison of Relief Therapeutics Holding's Moat Score

For the Biotechnology subindustry, Relief Therapeutics Holding's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Moat Score distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Moat Score falls into.

Save Embed

;

Save Embed

;

Relief Therapeutics Holding (OTCPK:RLFTY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Relief Therapeutics Holding Moat Score Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTY) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

RLFTF:USA RLFz:UK 0QKQ:UK V6M:Germany RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.